PHVS Stock — Pharvaris BV

Pharvaris BV (PHVS)

Updated October 16, 2026.

PHVS is a Stock. Total return is -4.3% over the past 5.7 years, 116.8 points behind SPY at 112.5%.

Pharvaris N.V. is a late-stage biopharmaceutical company developing therapies for rare diseases, specifically targeting bradykinin-mediated conditions such as hereditary angioedema and acquired angioedema; its lead candidate, deucrictibant, is in phase 3 trials in multiple formulations for treatment and prophylaxis. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to clinical-stage biotechnology development with potential for significant upside upon successful drug approval, though it carries the substantial risks inherent to companies with products not yet commercialized.

PHVS performance versus SPY

Price and return data through 2026-10-16.

Total return is -4.3% over the past 5.7 years, 116.8 points behind SPY at 112.5%. Over the past year its total return — price change plus distributions reinvested — is 26.9%. Its deepest 1-year drawdown was 28.6%.

PHVS key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2021

Distribution frequency

None

Last close

$27.74 (as of 2026-10-16)

Market cap

$1,947,472,996

Average volume

1307617.0

Beta

-2.461

Payout ratio

0.0%

EPS

$-3.06

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PHVS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.6%.

Who may consider PHVS — and who may not

It is a weaker fit for investors who need monthly cash flow (PHVS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PHVS

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions